Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells
Related Experiment Video
Updated: Sep 3, 2025
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Lorenzo Monteleone1, Barbara Marengo1,2, Francesca Musumeci3
1Department of Experimental Medicine (DIMES), General Pathology Section, University of Genoa, 16132 Genoa, Italy.
Abstract:
Glioblastoma (GBM) is the most common adult brain tumor and, although many efforts have been made to find valid therapies, the onset of resistance is the main cause of recurrence. Therefore, it is crucial to identify and target the molecular mediators responsible for GBM malignancy. In this context, the use of Src inhibitors such as SI306 (C1) and its prodrug (C2) showed promising results, suggesting that SI306 could be the lead compound useful to derivate new anti-GBM drugs. Therefore, a new prodrug of SI306 (C3) was synthesized and tested on CAS-1 and U87 human GBM cells by comparing its effect to that of C1 and C2. All compounds were more effective on CAS-1 than U87 cells, while C2 was the most active on both cell lines. Moreover, the anti-survival effect was associated with a reduction in the expression of epidermal growth factor receptor (EGFR)WT and EGFR-vIII in U87 and CAS-1 cells, respectively. Collectively, our findings demonstrate that all tested compounds are able to counteract GBM survival, further supporting the role of SI306 as progenitor of promising new drugs to treat malignant GBM.
Insights
New prodrugs targeting epidermal growth factor receptor (EGFR) show promise against glioblastoma (GBM). These compounds, derived from SI306, effectively reduced GBM cell survival, offering potential for novel glioblastoma therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Glioblastoma (GBM) is the most prevalent adult brain tumor, frequently recurring due to treatment resistance.
- Identifying molecular targets is crucial for developing effective GBM therapies.
- Src inhibitors, like SI306, have shown potential in targeting GBM malignancy.
Purpose of the Study:
- To synthesize and evaluate a novel SI306 prodrug (C3) against human GBM cells.
- To compare the efficacy of C3 with existing compounds (C1 and C2) in GBM treatment.
- To investigate the molecular mechanisms underlying the anti-GBM effects of these compounds.
Main Methods:
- Synthesis of a new SI306 prodrug (C3).
- In vitro testing of C1, C2, and C3 on CAS-1 and U87 human GBM cell lines.
- Assessment of cell survival and expression of epidermal growth factor receptor (EGFR) variants.
Main Results:
- All tested compounds (C1, C2, C3) demonstrated anti-GBM activity.
- Compound C2 exhibited the highest activity across both cell lines.
- The anti-survival effect correlated with reduced EGFR expression (EGFRWT in U87, EGFR-vIII in CAS-1).
Conclusions:
- The tested SI306 derivatives effectively counteract GBM cell survival.
- SI306 serves as a valuable lead compound for developing new anti-GBM drugs.
- Further research into these compounds could lead to improved glioblastoma therapies.
More Related Videos
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
12:25Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014